Help contribute to finding the first potential FDA-approved medication to treat meth use.
M3 is a Phase 1 clinical trial being conducted in both San Francisco and Los Angeles, looking at the safety of offering mirtazapine, a medication approved to treat depression, to people who use methamphetamine. Study participants will be closely monitored for 14 days in a hospital setting to evaluate the safety of taking mirtazapine.
Mirtazapine (Remeron©)has shown promise in helping people reduce their use of methamphetamine and cope with the effects of withdrawal and cravings for meth. It is not currently FDA-approved for this
purpose and this study will help to further evaluate its safety.
Some of the study participants will also be taking methadone to make sure that mirtazapine is safe with
both methamphetamine and opioids.
We know… A two-week hospital stay is a big commitment! FDA trials move in 3 phases before a drug can be approved for general use. The first phase looks intensively at how the drug works in the body – to make sure that it is safe in different situations. To do this phase right, study participants will need to be
in an environment where they can be observed continuously. Study staff will do everything we can to make the time you spend in the hospital pleasant, productive, and personalized for your needs.
There are medications to help people reduce tobacco use, alcohol use, and opioid use. These options mean that doctors can prescribe medications to people who are experiencing problems related to their
substance use – just like when someone has diabetes and they need treatment for high blood sugar. Unfortunately, there are no FDA-approved medications to help people who want to reduce methamphetamine use. This study is a critical step in changing that.
Your time and contribution are of tremendous value to public health research. Participants who are eligible and enroll, will be compensated up to $2430 for completing all study activities and procedures.
To see if you may be eligible to participate, call us at our San Francisco site, 628-217-6319 or if you are in the Los Angeles area, call 323-461-3106. You can also submit your information via the secure contact form, under the 'Contact Us" option at the top of the page to see if you might qualify. If you do, we will set up the first screening visit for you to come in to our office to see if you meet further study criteria. Determining study eligibility involves meeting with a research associate, clinical staff and various other procedures, which will be explained to you during the informed consent process.